20-SOLA

20-SOLA is an orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a Streptozotocin (STZ) (HY-13753) -diabetic mouse model. 20-SOLA facilitates the restoration of coronary collateral growth (CCG) after ischemic injury. 20-SOLA can be studied for research in cardiovascular diseases and diabetes[1].

Product Specifications

UNSPSC

12352211

Target

Cytochrome P450; Orphan Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Endocrinology; Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/20-sola.html

Purity

98.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COCCOCCOCCOCCOCCOCCOC(CCCC/C=C\CCCCCCC/C=C\CCCCO)=O

Molecular Formula

C33H62O9

Molecular Weight

602.84

References & Citations

[1]Pascale JV, et al. 20-Hydroxyeicosatetraenoic acid (20-HETE) : Bioactions, receptors, vascular function, cardiometabolic disease and beyond. Adv Pharmacol. 2023;97:229-255.|[2]Gilani, A., et al., (2021) . 20-HETE interferes with insulin signaling and contributes to obesity-driven insulin resistance. Prostaglandins & other lipid mediators, 152, 106485. |[3]Gilani, A., et al., (2018) . High-fat diet-induced obesity and insulin resistance in CYP4a14-/- mice is mediated by 20-HETE. American journal of physiology. Regulatory, integrative and comparative physiology, 315 (5), R934–R944.|[4]Gangadhariah, M. H., et al., (2015) . Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. Journal of the American Society of Nephrology: JASN, 26 (3), 597–610.